FBIO - Fortress Biotech Stock Price, News & Analysis

$4.00 -0.02 (-0.50 %)
(As of 11/24/2017 02:40 AM ET)
Previous Close$4.02
Today's Range$3.97 - $4.08
52-Week Range$1.88 - $5.13
Volume56,500 shs
Average Volume173,560 shs
Market Capitalization$203.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14

About Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech logoFortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.


Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:FBIO
CUSIP21976U10

Debt

Debt-to-Equity Ratio0.42%
Current Ratio2.69%
Quick Ratio2.69%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.48 million
Price / Sales12.30
Cash FlowN/A
Price / CashN/A
Book Value$2.39 per share
Price / Book1.67

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.83)
Net Income$-55,090,000.00
Net Margins-65.80%
Return on Equity-61.43%
Return on Assets-33.68%

Miscellaneous

Employees45
Outstanding Shares50,660,000

Frequently Asked Questions for Fortress Biotech (NASDAQ:FBIO)

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) posted its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.24. The biopharmaceutical company had revenue of $46.89 million for the quarter, compared to analyst estimates of $50.75 million. Fortress Biotech had a negative return on equity of 61.43% and a negative net margin of 65.80%. The company's revenue was up 4709.2% on a year-over-year basis. View Fortress Biotech's Earnings History.

Where is Fortress Biotech's stock going? Where will Fortress Biotech's stock price be in 2017?

4 analysts have issued 12 month price objectives for Fortress Biotech's stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate Fortress Biotech's share price to reach $11.00 in the next year. View Analyst Ratings for Fortress Biotech.

What are Wall Street analysts saying about Fortress Biotech stock?

Here are some recent quotes from research analysts about Fortress Biotech stock:

  • 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (10/10/2017)
  • 2. FBR & Co analysts commented, "On May 10, Fortress reported 1Q17 results. The company did not host a conference call, but we had a chance to catch up with the CEO. We note that Fortress made great progress in terms of advancing its pipeline in 2017. Recent company highlights include the launch of two additional subsidiaries in the quarter, Caelum Biosciences and Cyprium Therapeutics, thereby broadening the company pipeline to include amyloid light chain (AL) amyloidosis and Menkes disease indications. We expect the company to continue to advance its pipeline and explore additional opportunities to strengthen its subsidiary company portfolio for the rest of 2017." (5/12/2017)

Who are some of Fortress Biotech's key competitors?

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the folowing people:

  • Lindsay A. Rosenwald M.D., Chairman of the Board, President, Chief Executive Officer (Age 61)
  • Eric K. Rowinsky M.D., Vice Chairman of the Board (Age 60)
  • Robyn Hunter, Chief Financial Officer (Age 55)
  • Michael S. Weiss, Executive Vice Chairman - Strategic Development (Age 51)
  • Lucy Lu M.D., Executive Vice President (Age 40)
  • George C. Avgerinos Ph.D., Senior Vice President - Biologics Operations (Age 62)
  • Malcolm I. Hoenlein, Director (Age 73)
  • David J. Barrett CPA, , Independent Director (Age 39)
  • Jimmie Harvey Jr., M.D., Independent Director (Age 63)
  • J. Jay Lobell J.D., Independent Director (Age 52)

Who owns Fortress Biotech stock?

Fortress Biotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include Strs Ohio (0.27%), Wells Fargo & Company MN (0.24%) and Citadel Advisors LLC (0.05%). Company insiders that own Fortress Biotech stock include George Avgerinos and Lindsay A Md Rosenwald. View Institutional Ownership Trends for Fortress Biotech.

Who bought Fortress Biotech stock? Who is buying Fortress Biotech stock?

Fortress Biotech's stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Wells Fargo & Company MN and Citadel Advisors LLC. View Insider Buying and Selling for Fortress Biotech.

How do I buy Fortress Biotech stock?

Shares of Fortress Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of Fortress Biotech stock can currently be purchased for approximately $4.00.

How big of a company is Fortress Biotech?

Fortress Biotech has a market capitalization of $203.64 million and generates $16.48 million in revenue each year. The biopharmaceutical company earns $-55,090,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Fortress Biotech employs 45 workers across the globe.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Fortress Biotech (FBIO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Fortress Biotech (NASDAQ:FBIO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.00 (175.00% upside)

Consensus Price Target History for Fortress Biotech (NASDAQ:FBIO)

Price Target History for Fortress Biotech (NASDAQ:FBIO)

Analysts' Ratings History for Fortress Biotech (NASDAQ:FBIO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017HC WainwrightSet Price TargetBuy$11.00HighView Rating Details
7/11/2017Rodman & RenshawInitiated CoverageBuy -> Buy$11.00LowView Rating Details
7/4/2017FBR & CoReiterated RatingBuyMediumView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$11.00MediumView Rating Details
10/3/2016Roth CapitalInitiated CoverageBuy$9.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Fortress Biotech (NASDAQ:FBIO)

Earnings by Quarter for Fortress Biotech (NASDAQ:FBIO)

Earnings History by Quarter for Fortress Biotech (NASDAQ FBIO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.43)($0.67)$50.75 million$46.89 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.36)($0.30)$47.04 million$2.78 millionViewN/AView Earnings Details
8/9/2016Q2($0.29)($0.31)$1.07 million$2.23 millionViewN/AView Earnings Details
5/10/2016Q1($0.31)$0.66 millionViewN/AView Earnings Details
3/15/2016Q4($0.09)($0.31)$0.34 millionViewN/AView Earnings Details
11/9/2015Q315($0.13)($0.46)$0.03 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)ViewN/AView Earnings Details
5/11/2015Q1($0.31)ViewN/AView Earnings Details
3/16/2015Q414($0.10)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.17)($0.13)ViewN/AView Earnings Details
5/12/2014Q114($0.18)($0.21)ViewN/AView Earnings Details
3/14/2014Q413($0.22)($0.27)ViewN/AView Earnings Details
11/1/2013Q313($0.31)($0.24)ViewN/AView Earnings Details
8/5/2013Q213($0.31)($0.38)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.30)($0.35)ViewN/AView Earnings Details
3/14/2013Q4 2012($0.27)($0.36)ViewN/AView Earnings Details
11/14/2012Q312($0.28)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Fortress Biotech (NASDAQ:FBIO)
2017 EPS Consensus Estimate: ($1.47)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.37)($0.37)($0.37)
Q3 20171($0.38)($0.38)($0.38)
Q4 20171($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fortress Biotech (NASDAQ:FBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Fortress Biotech (NASDAQ FBIO)

Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 12.34%
Insider Trades by Quarter for Fortress Biotech (NASDAQ:FBIO)
Insider Trades by Quarter for Fortress Biotech (NASDAQ:FBIO)

Insider Trades by Quarter for Fortress Biotech (NASDAQ FBIO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/6/2017Lindsay A Md RosenwaldCEOBuy40,000$25.00$1,000,000.00View SEC Filing  
9/16/2016George AvgerinosSVPSell48,912$2.55$124,725.60View SEC Filing  
12/1/2014Lucy LuCFOBuy5,000$1.45$7,250.00View SEC Filing  
11/6/2014Lindsay A Md RosenwaldCEOBuy150,000$1.61$241,500.00View SEC Filing  
11/6/2014Malcolm HoenleinDirectorBuy25,000$1.61$40,250.00View SEC Filing  
11/6/2014Michael S WeissMajor ShareholderBuy1,000,000$1.61$1,610,000.00View SEC Filing  
6/2/2014Lucy LuCFOBuy5,000$1.37$6,850.00View SEC Filing  
4/22/2014Kevin HorganInsiderSell47,566$1.89$89,899.74View SEC Filing  
4/21/2014Kevin HorganInsiderSell19,000$1.81$34,390.00View SEC Filing  
8/21/2013J Jay LobellDirectorBuy5,000$7.37$36,850.00View SEC Filing  
7/17/2013Lucy LuCFOBuy4,545$7.90$35,905.50View SEC Filing  
6/20/2013J Jay LobellDirectorBuy10,000$7.62$76,200.00View SEC Filing  
5/31/2013Dale RitterCAOBuy1,503$3.88$5,831.64View SEC Filing  
5/31/2013Lucy LuCFOBuy4,979$3.88$19,318.52View SEC Filing  
5/31/2013Noah D BeermanCOOBuy5,000$3.88$19,400.00View SEC Filing  
1/14/2013Harlan F WeismanCEOBuy20,000$5.71$114,200.00View SEC Filing  
11/30/2012Glenn L Md CooperInsiderBuy3,811$4.02$15,320.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Fortress Biotech (NASDAQ FBIO)

Source:
DateHeadline
Mustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate HighlightsMustang Bio Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - November 14 at 6:59 PM
Mustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate ControllerMustang Bio Announces Appointment of Brian Achenbach as Vice President of Finance and Corporate Controller
finance.yahoo.com - November 14 at 6:59 PM
Fortress Biotech, Inc. (FBIO) Receives Consensus Rating of "Buy" from BrokeragesFortress Biotech, Inc. (FBIO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 13 at 8:14 AM
Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)
globenewswire.com - November 11 at 8:44 AM
Fortress Biotech, Inc. (FBIO) Posts  Earnings Results, Misses Expectations By $0.24 EPSFortress Biotech, Inc. (FBIO) Posts Earnings Results, Misses Expectations By $0.24 EPS
www.americanbankingnews.com - November 10 at 7:32 PM
Fortress Biotech reports 3Q lossFortress Biotech reports 3Q loss
finance.yahoo.com - November 10 at 2:45 PM
Fortress Biotech (FBIO) Announces Cellvations CEVA101 Granted ... - StreetInsider.comFortress Biotech (FBIO) Announces Cellvation's CEVA101 Granted ... - StreetInsider.com
www.streetinsider.com - November 9 at 2:58 AM
Fortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative Medicine Advanced Therapy Designation for the Treatment of Traumatic Brain InjuryFortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative Medicine Advanced Therapy Designation for the Treatment of Traumatic Brain Injury
finance.yahoo.com - November 9 at 2:58 AM
Insider Buying: Fortress Biotech, Inc. (FBIO) CEO Buys 40,000 Shares of StockInsider Buying: Fortress Biotech, Inc. (FBIO) CEO Buys 40,000 Shares of Stock
www.americanbankingnews.com - November 8 at 6:50 PM
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering - GlobeNewswire (press release)Fortress Biotech Announces Pricing of Series A Preferred Stock Offering - GlobeNewswire (press release)
globenewswire.com - November 8 at 6:51 AM
Fortress Biotech Announces Subsidiary Data to Be Presented at 59th American Society of Hematology Annual Meeting - GlobeNewswire (press release)Fortress Biotech Announces Subsidiary Data to Be Presented at 59th American Society of Hematology Annual Meeting - GlobeNewswire (press release)
globenewswire.com - November 2 at 5:44 AM
Mustang Bio (MBIO) Reports Preclinical Data on Regional Delivery of MB-103 HER2 CAR T Cells to Target HER2+ Breast Cancer Metastasis to BrainMustang Bio (MBIO) Reports Preclinical Data on Regional Delivery of MB-103 HER2 CAR T Cells to Target HER2+ Breast Cancer Metastasis to Brain
www.streetinsider.com - November 1 at 7:40 PM
Mustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual MeetingMustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 7:40 PM
Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual MeetingCaelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 7:40 PM
Data support clinical development of MB-103 HER2 CAR T cell therapyData support clinical development of MB-103 HER2 CAR T cell therapy
globenewswire.com - October 31 at 7:46 PM
Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the BrainMustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain
finance.yahoo.com - October 31 at 7:46 PM
Fortress Biotech, Inc. (FBIO) Scheduled to Post Quarterly Earnings on TuesdayFortress Biotech, Inc. (FBIO) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:34 AM
ETFs with exposure to Fortress Biotech, Inc. : October 30, 2017ETFs with exposure to Fortress Biotech, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 7:24 PM
Fortress Biotech Is Now Oversold (FBIO)Fortress Biotech Is Now Oversold (FBIO)
www.thestreet.com - October 20 at 5:05 PM
ETFs with exposure to Fortress Biotech, Inc. : October 20, 2017ETFs with exposure to Fortress Biotech, Inc. : October 20, 2017
finance.yahoo.com - October 20 at 5:05 PM
Fortress Biotech, Inc. (FBIO) Given Consensus Rating of "Buy" by BrokeragesFortress Biotech, Inc. (FBIO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 19 at 10:46 AM
Fortress Biotech, Inc. (FBIO) Short Interest Down 55.2% in SeptemberFortress Biotech, Inc. (FBIO) Short Interest Down 55.2% in September
www.americanbankingnews.com - October 14 at 2:04 AM
Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of ... - GlobeNewswire (press release)Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of ... - GlobeNewswire (press release)
globenewswire.com - October 12 at 7:27 PM
Mustang research partner City of Hope awarded California Institute for Regenerative Medicine grant to support ongoing Phase 1 studyMustang research partner City of Hope awarded California Institute for Regenerative Medicine grant to support ongoing Phase 1 study
www.nasdaq.com - October 11 at 8:06 PM
Fortress Biotech Stock Sees Short Interest Move 55.2% LowerFortress Biotech Stock Sees Short Interest Move 55.2% Lower
www.thestreet.com - October 11 at 8:06 PM
Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant GliomaMustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma
finance.yahoo.com - October 11 at 8:06 PM
ETFs with exposure to Fortress Biotech, Inc. : October 9, 2017ETFs with exposure to Fortress Biotech, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 6:50 PM
Fortress Biotech, Inc. :FBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017Fortress Biotech, Inc. :FBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 6:59 PM
Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301 - GlobeNewswire (press release)Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301 - GlobeNewswire (press release)
globenewswire.com - October 5 at 9:13 AM
Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301
finance.yahoo.com - October 5 at 9:13 AM
Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative PainAvenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain
finance.yahoo.com - October 2 at 2:40 PM
Reviewing VIVUS (VVUS) & Fortress Biotech (FBIO)Reviewing VIVUS (VVUS) & Fortress Biotech (FBIO)
www.americanbankingnews.com - October 1 at 4:38 PM
Fortress Biotech (FBIO) vs. KalVista Pharmaceuticals (KALV) Head to Head SurveyFortress Biotech (FBIO) vs. KalVista Pharmaceuticals (KALV) Head to Head Survey
www.americanbankingnews.com - September 28 at 8:30 PM
Topline data readout expected in the second quarter of 2018Topline data readout expected in the second quarter of 2018
globenewswire.com - September 28 at 1:12 PM
Fortress Biotech, Inc. (FBIO) Given Average Recommendation of "Buy" by AnalystsFortress Biotech, Inc. (FBIO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 24 at 6:48 AM
Comparing Fortress Biotech (FBIO) and Vericel Corporation (VCEL)Comparing Fortress Biotech (FBIO) and Vericel Corporation (VCEL)
www.americanbankingnews.com - September 22 at 10:06 PM
Fortress Biotech (FBIO) versus MediWound (MDWD) Critical ComparisonFortress Biotech (FBIO) versus MediWound (MDWD) Critical Comparison
www.americanbankingnews.com - September 17 at 4:26 AM
Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed ImmunotherapiesMustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
finance.yahoo.com - September 14 at 7:15 PM
Mustang Bio to Present at the CAR-TCR Summit 2017 - GlobeNewswire (press release)Mustang Bio to Present at the CAR-TCR Summit 2017 - GlobeNewswire (press release)
globenewswire.com - September 7 at 4:35 AM
Fortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment ConferenceFortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 5 at 8:11 PM
Fortress Biotech, Inc. (FBIO) Given Average Rating of "Buy" by BrokeragesFortress Biotech, Inc. (FBIO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 6:46 AM
ChemoCentryx (CCXI) and Fortress Biotech (FBIO) Critical AnalysisChemoCentryx (CCXI) and Fortress Biotech (FBIO) Critical Analysis
www.americanbankingnews.com - August 29 at 10:42 AM
Mustang Bio Commences Trading on the NASDAQ Global Market - NasdaqMustang Bio Commences Trading on the NASDAQ Global Market - Nasdaq
www.nasdaq.com - August 24 at 4:58 AM
Mustang Bio (MBIO) Commences TradingMustang Bio (MBIO) Commences Trading
www.streetinsider.com - August 23 at 11:56 PM
Mustang Bio Commences Trading on the NASDAQ Global Market - GlobeNewswire (press release)Mustang Bio Commences Trading on the NASDAQ Global Market - GlobeNewswire (press release)
globenewswire.com - August 23 at 12:08 AM
Mustang Bio Commences Trading on the NASDAQ Global MarketMustang Bio Commences Trading on the NASDAQ Global Market
finance.yahoo.com - August 22 at 7:06 PM
Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate ... - GlobeNewswire (press release)Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate ... - GlobeNewswire (press release)
globenewswire.com - August 17 at 4:44 AM
Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)
globenewswire.com - August 14 at 6:55 PM
Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments ... - GlobeNewswire (press release)Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments ... - GlobeNewswire (press release)
globenewswire.com - August 14 at 6:55 PM
Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate HighlightsMustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 14 at 6:55 PM

Social Media

Financials

Chart

Fortress Biotech (NASDAQ FBIO) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.